5 Key Takeaways

• 1

  OpRegen RPE cell therapy demonstrated sustained anatomical and functional improvements in geographic atrophy over 36 months.

• 2

  Patients treated with OpRegen showed an average gain of +9 ETDRS letters in visual acuity after a single administration.

• 3

  Greater visual acuity improvements correlated with more extensive coverage of the geographic atrophy area by the OpRegen cells.

• 4

  Sustained structural improvements in retinal layers were observed in treated eyes, indicating a functional and structural relationship.

• 5

  Safety outcomes were manageable, with uncommon adverse events, and the phase 2a GAlette study aims to optimize surgical delivery methods.